Responses
Clinical therapeutics
Clinical therapeutics
Q01 SIRT 1 mediated modulation of circulating cytokines in huntington's disease- pharmacodynamics results from phase 1B study of selisistat—A SIRT 1 inhibitor
Compose a Response to This Article
Other responses
No responses have been published for this article.